{"brief_title": "A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis", "brief_summary": "The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid clotting of the graft and of the haemodialysis machine.", "condition": ["Chronic Kidney Failure", "Vascular Graft Occlusion"], "intervention_type": ["Drug"], "intervention_name": ["PEG-hirudin"], "criteria": "- Patients undergoing chronic haemodialysis via an arteriovenous graft - Arteriovenous graft in place for at least 3 months - Duration of haemodialysis of at least 3 months, with 3 full dialysis sessions per week with a duration between 2 and 5 hours per session - Women patients must be either postmenopausal for more than 1 year or, if of childbearing age, must use adequate contraception - Women patients must have a negative serum pregnancy test within one week of randomisation - Able to provide written informed consent prior to study participation", "gender": "All", "minimum_age": "21 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "keyword": "Hemodialysis", "mesh_term": ["Renal Insufficiency", "Kidney Failure, Chronic", "Graft Occlusion, Vascular", "Heparin", "Hirudins"], "id": "NCT00074620"}